Press Releases

BOSTON, Sept. 16, 2019 /PRNewswire/ -- Oncoheroes Biosciences Inc. ("Oncoheroes") and Boehringer Ingelheim International GmbH ("Boehringer Ingelheim") have signed a worldwide, exclusive licensing agreement for volasertib, an investigational anti-cancer compound that was originally discovered and developed by Boehringer Ingelheim. Under the terms of this agreement Boehri

BOTHELL, Wash., Sept. 16, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction t

SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that

SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has executed an exclusive worldwide license agreement with Novartis under which Amplyx has acquired the rights to the Phas

SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in pati

MAHWAH, N.J., Sept. 16, 2019 /PRNewswire/ -- Glenmark Pharmaceuticals (Glenmark), a research-led, integrated global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma who have received prior ther

SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that

WASHINGTON, Sept. 16, 2019 /PRNewswire/ -- Hyundai Hope On Wheels® (HHOW), a 501(c)(3) non-profit organization supported by Hyundai and its U.S. dealer

BOSTON, Sept. 16, 2019 /PRNewswire/ -- Firefly Health, a technology-powered concierge medicine service for average Americans, announced today it has closed $10.2 m

BOTHELL, Wash. and TOKYO, Sept. 16, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq:SGEN) and